Patent · US Active

Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors

US9783539B2 · kind B2 · utility

1Cited by

0References

20Claims

0Family size

Assignee

JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. · CN

Inventors

Jianyong Chen · Tangxia, CN
Yunlong Zhou · Suzhou, CN
Shaomeng Wang · Saline, US
Ming Guo · Suzhou, CN
Dajun Yang · Suzhou, CN
Lingling Jiao · Taizhou City, CN
Yu Jing · Suzhou, CN
Xu Qian · 安丰镇, CN
Liu Liu · San Diego, US
Longchuan Bai · Ann Arbor, US
Chao-Yie Yang · Hangzhou City, CN
Donna McEachern · Ann Arbor, US

Key dates

Filing date	Feb 27, 2014
Grant date	Oct 10, 2017
Priority date	—
Expiry date	Feb 27, 2034

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are certain indoloquinolone compounds, methods of preparation thereof, pharmaceutical compositions thereof, and uses thereof, such as their uses as ALK inhibitors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.